Comparative safety review of current pharmacological treatments for interstitial cystitis/ bladder pain syndrome

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21(2):167–178.
   PubMed Web of Science ®Google Scholar
• Hanno PM, Erickson D, Moldwin R, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015 May;193(5):1545–1553.
   PubMed Web of Science ®Google Scholar
• Fan YH, Lin AT, Lu SH, et al. Non-bladder conditions in female Taiwanese patients with interstitial cystitis/hypersensitive bladder syndrome. Int J Urol. 2014 Aug;21(8):805–809.
   PubMed Web of Science ®Google Scholar
• Van De Merwe JP. Interstitial cystitis and systemic autoimmune diseases. Nat Clin Pract Urol. 2007 Sep;4(9):484–491.
   PubMedGoogle Scholar
• Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011 Aug;186(2):540–544.
   PubMed Web of Science ®Google Scholar
• Suskind AM, Berry SH, Ewing BA, et al. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND interstitial cystitis epidemiology male study. J Urol. 2013 Jan;189(1):141–145.
   PubMed Web of Science ®Google Scholar
• Homma Y, Akiyama Y, Tomoe H, et al. Clinical guidelines for interstitial cystitis/bladder pain syndrome. Int J Urol. 2020 Jul;27(7):578–589.
   PubMed Web of Science ®Google Scholar
• Lee MH, Chang KM, Tsai WC. Morbidity rate and medical utilization in interstitial cystitis/painful bladder syndrome. Int Urogynecol J. 2018 Jul;29(7):1045–1050.
   PubMed Web of Science ®Google Scholar
• Leppilahti M, Tammela TL, Huhtala H, et al. Prevalence of symptoms related to interstitial cystitis in women: a population based study in Finland. J Urol. 2002 Jul;168(1):139–143.
   PubMed Web of Science ®Google Scholar
• Hakimi Z, Houbiers J, Pedersini R, et al. The burden of bladder pain in five european countries: a cross-sectional study. Urology. 2017 Jan;99:84–91.
   PubMed Web of Science ®Google Scholar
• O’Leary MP, Sant GR, Fowler FJ Jr., et al. The interstitial cystitis symptom index and problem index. Urology. 1997 May;49(5A Suppl):58–63.
   PubMed Web of Science ®Google Scholar
• Braunstein R, Shapiro E, Kaye J, et al. The role of cystoscopy in the diagnosis of Hunner’s ulcer disease. J Urol. 2008 Oct;180(4):1383–1386.
   PubMed Web of Science ®Google Scholar
• Van De Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008 Jan;53(1):60–67.
   PubMed Web of Science ®Google Scholar
• Mb C, Moreira CG, Sperandio V. Toward a validated diagnostic test with machine learning algorithm for interstitial cystitis. Urol Sci. 2014;25(1):1–8.
   PubMedGoogle Scholar
• Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013 Apr;93(2):653–680.
   PubMed Web of Science ®Google Scholar
• Parsons CL. The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain. BJU Int. 2011 Feb;107(3):370–375.
   PubMed Web of Science ®Google Scholar
• Hauser PJ, Dozmorov MG, Bane BL, et al. Abnormal expression of differentiation related proteins and proteoglycan core proteins in the urothelium of patients with interstitial cystitis. J Urol. 2008 Feb;179(2):764–769.
   PubMed Web of Science ®Google Scholar
• Shie JH, Liu HT, Kuo HC. Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome. Urology. 2012 Feb;79(2):e7–13. 484
   Web of Science ®Google Scholar
• Kim J, Keay SK, Freeman MR. Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation. BJU Int. 2009 Feb;103(4):541–546.
   PubMed Web of Science ®Google Scholar
• Peeker R, Enerbäck L, Fall M, et al. Recruitment, distribution and phenotypes of mast cells in interstitial cystitis. J Urol. 2000 Mar;163(3):1009–1015.
   PubMed Web of Science ®Google Scholar
• Grundy L, Caldwell A, Garcia Caraballo S, et al. Histamine induces peripheral and central hypersensitivity to bladder distension via the histamine H(1) receptor and TRPV1. Am J Physiol Renal Physiol. 2020 Feb 1;318(2):F298–f314.
   PubMed Web of Science ®Google Scholar
• Schrepf A, O’Donnell MA, Luo Y, et al. Inflammation and symptom change in interstitial cystitis or bladder pain syndrome: a multidisciplinary approach to the study of chronic pelvic pain research network study. Urology. 2016 Apr;90:56–61.
   PubMed Web of Science ®Google Scholar
• Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states–maybe it is all in their head. Best Pract Res Clin Rheumatol. 2011 Apr;25(2):141–154.
   PubMed Web of Science ®Google Scholar
• Warren JW, Van De Merwe JP, Nickel JC. Interstitial cystitis/bladder pain syndrome and nonbladder syndromes: facts and hypotheses. Urology. 2011 Oct;78(4):727–732.
   PubMed Web of Science ®Google Scholar
• Jhang JF, Kuo HC. Pathomechanism of interstitial cystitis/bladder pain syndrome and mapping the heterogeneity of disease. Int Neurourol J. 2016 Nov;20(Suppl 2):S95–104.
   PubMed Web of Science ®Google Scholar
• Van Ophoven A, Vonde K, Koch W, et al. Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials. Curr Med Res Opin. 2019 Sep;35(9):1495–1503.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Barkin J, Forrest J, et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology. 2005 Apr;65(4):654–658.
   PubMed Web of Science ®Google Scholar
• Pearce WA, Chen R, Jain N. Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium. Ophthalmology. 2018 Nov;125(11):1793–1802.
   PubMed Web of Science ®Google Scholar
• Hanif AM, Armenti ST, Taylor SC, et al. Phenotypic spectrum of pentosan polysulfate sodium-associated maculopathy: a multicenter study. JAMA Ophthalmol. 2019 Sep 5;137(11):1275–1282.
   PubMed Web of Science ®Google Scholar
• Hanif AM, Shah R, Yan J, et al. Strength of Association between Pentosan Polysulfate and a Novel Maculopathy. Ophthalmology. 2019 Oct;126(10):1464–1466.
   PubMed Web of Science ®Google Scholar
• Tirlapur SA, Birch JV, Carberry CL, Khan KS, Latthe PM, Jha S, Ward KL, Irving A on behalf ofthe Royal College of Obstetricians and Gynaecologists. Management of bladder pain syndrome. BJOG 2016; 124:e46–e72
   Google Scholar
• Van Ophoven A, Pokupic S, Heinecke A, et al. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004 Aug;172(2):533–536.
   PubMed Web of Science ®Google Scholar
• Foster HE Jr., Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010 May;183(5):1853–1858.
   PubMed Web of Science ®Google Scholar
• Jc. N. Tricyclic and tetracyclic drugs. In: The American psychiatric publishing textbook of psychopharmacology, 4th ed. 2009; Washington, DC: American Psychiatric Publishing. P.467–477
   Google Scholar
• Ray WA, Meredith S, Thapa PB, et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004 Mar;75(3):234–241.
   PubMed Web of Science ®Google Scholar
• Güloglu C, Orak M, Ustündag M, et al. Analysis of amitriptyline overdose in emergency medicine. Emerg Med J. 2011 Apr;28(4):296–299.
   PubMed Web of Science ®Google Scholar
• Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737–748.
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Sant GR. Hydroxyzine therapy for interstitial cystitis. Urology. 1997 May;49(5A Suppl):108–110.
   PubMed Web of Science ®Google Scholar
• Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003 Sep;170(3):810–815.
   PubMed Web of Science ®Google Scholar
• Thilagarajah R, Witherow RO, Walker MM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. BJU Int. 2001 Feb;87(3):207–212.
   PubMed Web of Science ®Google Scholar
• Strom BL, Carson JL, Schinnar R, et al. Is cimetidine associated with neutropenia? Am J Med. 1995 Sep;99(3):282–290.
   PubMed Web of Science ®Google Scholar
• Larsson R, Bodemar G, Kågedal B, et al. The effects of cimetidine (Tagamet) on renal function in patients with renal failure. Acta medica Scandinavica. 1980;208(1–2):27–31.
   PubMedGoogle Scholar
• Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013 Dec 11;310(22):2435–2442.
   PubMed Web of Science ®Google Scholar
• Schlit AF, Delaunois A, Colomar A, et al. Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug. Pharmacol Res Perspect. 2017 Jun;5(3):e00309.
   PubMed Web of Science ®Google Scholar
• Kumar SL, Rai R. Hydroxyzine-induced acute generalized exanthematous pustulosis: an uncommon side effect of a common drug. Indian J Dermatol. 2011 Jul;56(4):447–448.
   PubMedGoogle Scholar
• Oravisto KJ, Alfthan OS. Treatment of interstitial cystitis with immunosuppression and chloroquine derivatives. Eur Urol. 1976;2(2):82–84.
   PubMedGoogle Scholar
• Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. J Urol. 2012 Oct;188(4):1186–1191.
   PubMed Web of Science ®Google Scholar
• Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005 Dec;174(6):2235–2238.
   PubMed Web of Science ®Google Scholar
• Moran PA, Dwyer PL, Carey MP, et al. Oral methotrexate in the management of refractory interstitial cystitis. Aust N Z J Obstet Gynaecol. 1999 Nov;39(4):468–471.
   PubMed Web of Science ®Google Scholar
• Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol. 2004 Jun;171(6 Pt 1):2138–2141.
   PubMed Web of Science ®Google Scholar
• Evans RJ. Treatment approaches for interstitial cystitis: multimodality therapy. Rev Urol. 2002;1((Suppl 1)):S16–20. 4 Suppl
   Google Scholar
• Chen H, Wang F, Chen W, et al. Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of a randomized, double-blind, placebo-controlled trial–treatment of interstitial cystitis/painful bladder syndrome with low-dose sildenafil. Urology. 2014 Jul;84(1):51–56.
   PubMed Web of Science ®Google Scholar
• Bosch PC, Randomized A. Double-blind, placebo-controlled trial of certolizumab pegol in women with refractory interstitial cystitis/bladder pain syndrome. Eur Urol. 2018 Nov;74(5):623–630.
   PubMed Web of Science ®Google Scholar
• Korting GE, Smith SD, Wheeler MA, et al. A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. J Urol. 1999 Feb;161(2):558–565.
   PubMed Web of Science ®Google Scholar
• Van Ophoven A, Hertle L. The dual serotonin and noradrenaline reuptake inhibitor duloxetine for the treatment of interstitial cystitis: results of an observational study. J Urol. 2007 Feb;177(2):552–555.
   PubMed Web of Science ®Google Scholar
• Bouchelouche K, Nordling J, Hald T, et al. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. J Urol. 2001 Nov;166(5):1734–1737.
   PubMed Web of Science ®Google Scholar
• Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014 Jan;191(1):77–82.
   PubMed Web of Science ®Google Scholar
• Ueda T, Homma Y, Yoshimura N. Suplatast tosilate in patients with interstitial cystitis: efficacy and treatment possibilities, with suggestions for future assessments. Int J Urol. 2019 Jun;26(Suppl 1):4–11.
   PubMed Web of Science ®Google Scholar
• Cervigni M. Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol. 2015 Dec;4(6):638–642.
   PubMed Web of Science ®Google Scholar
• Barua JM, Arance I, Angulo JC, et al. A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2016 Aug;27(8):1137–1147.
   PubMed Web of Science ®Google Scholar
• Wyndaele JJJ, Riedl C, Taneja R, et al. GAG replenishment therapy for bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2019 Feb;38(2):535–544.
   PubMed Web of Science ®Google Scholar
• Saida T, Yamamura T, Kondo T, et al. A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries. BMC Neurol. 2019 Jan 7;19(1):5.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Moldwin R, Lee S, et al. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009 Apr;103(7):910–918.
   PubMed Web of Science ®Google Scholar
• Davis EL, El Khoudary SR, Talbott EO, et al. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J Urol. 2008 Jan;179(1):177–185.
   PubMed Web of Science ®Google Scholar
• Kuo HC. Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and interstitial cystitis. J Formos Med Assoc. 2001 May;100(5):309–314.
   PubMed Web of Science ®Google Scholar
• Parsons CL, Housley T, Schmidt JD, et al. Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994 May;73(5):504–507.
   PubMedGoogle Scholar
• Van Ophoven A, Heinecke A, Hertle L. Safety and efficacy of concurrent application of oral pentosan polysulfate and subcutaneous low-dose heparin for patients with interstitial cystitis. Urology. 2005 Oct;66(4):707–711.
   PubMed Web of Science ®Google Scholar
• Parsons CL, Zupkas P, Proctor J, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med. 2012 Jan;9(1):207–212.
   PubMed Web of Science ®Google Scholar
• Welk BK, Teichman JM. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008 Jan;71(1):67–70.
   PubMed Web of Science ®Google Scholar
• Engelhardt PF, Morakis N, Daha LK, et al. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2011 Apr;22(4):401–405.
   PubMed Web of Science ®Google Scholar
• Lai MC, Kuo YC, Kuo HC. Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: a comparative randomized assessment of different regimens. Int J Urol. 2013 Feb;20(2):203–207.
   PubMed Web of Science ®Google Scholar
• Giberti C, Gallo F, Cortese P, et al. Combined intravesical sodium hyaluronate/chondroitin sulfate therapy for interstitial cystitis/bladder pain syndrome: a prospective study. Ther Adv Urol. 2013 Aug;5(4):175–179.
   PubMedGoogle Scholar
• Gülpınar O, Kayış A, Süer E, et al. Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis. Can Urol Assoc J. 2014 Sep;8(9–10):E610–4.
   PubMed Web of Science ®Google Scholar
• Porru D, Cervigni M, Nasta L, et al. Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of interstitial cystitis/painful bladder syndrome. Rev Recent Clin Trials. 2008 May;3(2):126–129.
   PubMedGoogle Scholar
• Porru D, Leva F, Parmigiani A, et al. Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2012 Sep;23(9):1193–1199.
   PubMed Web of Science ®Google Scholar
• Riedl CR, Engelhardt PF, Daha KL, et al. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecology J Pelvic Floor Dysfunction. 2008 May; 19(5):717–721.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Egerdie B, Downey J, et al. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int. 2009 Jan;103(1):56–60.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Egerdie RB, Steinhoff G, et al. Randomized, double-blind, parallel group pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with interstitial cystitis/painful bladder syndrome. Urology. 2010;76(4):804–809.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Hanno P, Kumar K, et al. Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology. 2012 Jun;79(6):1220–1224.
   PubMed Web of Science ®Google Scholar
• Thakkinstian A, Nickel JC. Efficacy of intravesical chondroitin sulphate in treatment of interstitial cystitis/bladder pain syndrome (IC/BPS): individual patient data (IPD) meta-analytical approach. Can Urol Assoc J. 2013 May-Jun;7(5–6):195–200.
   PubMed Web of Science ®Google Scholar
• Steinhoff G, Ittah B, Rowan S. The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol. 2002 Feb;9(1):1454–1458.
   PubMedGoogle Scholar
• Stellavato A, Pirozzi AVA, Diana P, et al. Hyaluronic acid and chondroitin sulfate, alone or in combination, efficiently counteract induced bladder cell damage and inflammation. PloS One. 2019;14(6):e0218475.
   PubMed Web of Science ®Google Scholar
• Cervigni M, Natale F, Nasta L, et al. Intravesical hyaluronic acid and chondroitin sulphate for bladder pain syndrome/interstitial cystitis: long-term treatment results. Int Urogynecol J. 2012 Sep;23(9):1187–1192.
   PubMed Web of Science ®Google Scholar
• Pyo JS, Cho WJ. Systematic review and meta-analysis of intravesical hyaluronic acid and hyaluronic acid/chondroitin sulfate instillation for interstitial cystitis/painful bladder syndrome. Cell Physiol Biochem. 2016;39(4):1618–1625.
   PubMedGoogle Scholar
• Rawls WF, Cox L, Rovner ES. Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: a review. Neurourol Urodyn. 2017 Sep;36(7):1677–1684.
   PubMed Web of Science ®Google Scholar
• Perez-Marrero R, Emerson LE, Feltis JT, et al. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140(1):36–39.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Homma Y, Tomoe H, Otsuka A, Kitta T, Masumori N, et al. Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis/bladder pain syndrome in Japanese patients: A multicenter, randomized, double-blind, placebo-controlled, clinical study. International Journal of Urology. https://doi.org/10.1111/iju.14505
   Google Scholar
• Sairanen J, Leppilahti M, Tammela TL, et al. Evaluation of health-related quality of life in patients with painful bladder syndrome/interstitial cystitis and the impact of four treatments on it. Scand J Urol. 2009;43(3):212–219.
   Web of Science ®Google Scholar
• Peeker R, Haghsheno MA, Holmäng S, et al. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol. 2000 Dec;164(6):15–16. 1912–5; discussion
   Web of Science ®Google Scholar
• Cervigni M, Sommariva M, Tenaglia R, et al. A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2017 Apr;36(4):1178–1186.
   PubMed Web of Science ®Google Scholar
• Tutolo M, Ammirati E, Castagna G, et al. A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroïtin sulphate 2% for painful bladder syndrome/interstitial cystitis. Int Braz J Urol. 2017 Jan-Feb;43(1):134–141.
   PubMed Web of Science ®Google Scholar
• Jhang JF, Kuo HC. Botulinum toxin a and lower urinary tract dysfunction: pathophysiology and mechanisms of action. Toxins (Basel). 2016 Apr 21;8(4):120.
   PubMed Web of Science ®Google Scholar
• Kuo HC, Jiang YH, Tsai YC, et al. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment - A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2016 Jun;35(5):609–614.
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Gubbiotti M, Bini V. Botulinum neurotoxin a intravesical injections in interstitial cystitis/bladder painful syndrome: a systematic review with meta-analysis. Toxins (Basel). 2019;11(9):510.
   Web of Science ®Google Scholar
• Pinto RA, Costa D, Morgado A, et al. Intratrigonal onabotulinumtoxina improves bladder symptoms and quality of life in patients with bladder pain syndrome/interstitial cystitis: a pilot, single center, randomized, double-blind, placebo controlled trial. J Urol. 2018 Apr;199(4):998–1003.
   PubMed Web of Science ®Google Scholar
• Kuo H-C, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009 Sep;104(5):657–661.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Kuo HC. Adverse events of intravesical onabotulinumtoxina injection between patients with overactive bladder and interstitial cystitis–different mechanisms of action of botox on bladder dysfunction? Toxins (Basel). 2016 Mar 16;8:3.
   Web of Science ®Google Scholar
• Chen PY, Lee WC, Wang HJ, et al. Therapeutic efficacy of onabotulinumtoxina delivered using various approaches in sensory bladder disorder. Toxins (Basel). 2020 Jan 23;12:2.
   Web of Science ®Google Scholar
• Chuang YC, Kuo HC, Prospective A. Multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxina for interstitial cystitis/bladder pain syndrome. J Urol. 2017 Aug;198(2):376–382.
   PubMed Web of Science ®Google Scholar